Literature DB >> 21651440

Prophylactic cancer vaccination by targeting functional non-self.

Vincent K Tuohy1, Ritika Jaini.   

Abstract

Despite the monumental success of childhood prophylactic vaccination, there is no similar program designed to provide protection as we age against adult onset diseases like breast cancer. Instead, the predominant focus of current cancer vaccine strategy is to vaccinate after the tumors become established. This strategy has at best provided incremental improvement in overall survival. We propose the development of an adult vaccination program modeled on the childhood program that provides protection against diseases we confront as we enter our middle age. Since most cases of adult cancers are not associated with definitive etiopathogenic viruses, we propose extending our selection of vaccine targets to tissue-specific self proteins that are over-expressed in developing tumors but are no longer expressed in normal tissues ('retired or former self'), are expressed in normal tissues under readily avoidable conditions ('conditional self'), or are incapable of targeting any clinically significant autoimmune complications ('irrelevant self'). By extending prophylactic vaccination to such "functional non-self" targets, prophylactic vaccination against adult onset diseases like breast cancer may occur safely in the absence of any autoimmune inflammatory complications and may potentially reduce disease incidence in a manner that mimics the impact of childhood vaccination on diseases like measles and polio.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21651440      PMCID: PMC3203523          DOI: 10.3109/07853890.2011.565065

Source DB:  PubMed          Journal:  Ann Med        ISSN: 0785-3890            Impact factor:   4.709


  71 in total

1.  Human mammary tumor virus in inflammatory breast cancer.

Authors:  Beatriz G-T Pogo; James F Holland; Paul H Levine
Journal:  Cancer       Date:  2010-06-01       Impact factor: 6.860

Review 2.  Aire.

Authors:  Diane Mathis; Christophe Benoist
Journal:  Annu Rev Immunol       Date:  2009       Impact factor: 28.527

3.  JC virus infection: a cause of colorectal cancer?

Authors:  Dana E Rollison
Journal:  J Clin Gastroenterol       Date:  2010-08       Impact factor: 3.062

Review 4.  Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination.

Authors:  D J West; G B Calandra
Journal:  Vaccine       Date:  1996-08       Impact factor: 3.641

5.  An autoimmune-mediated strategy for prophylactic breast cancer vaccination.

Authors:  Ritika Jaini; Pavani Kesaraju; Justin M Johnson; Cengiz Z Altuntas; Daniel Jane-Wit; Vincent K Tuohy
Journal:  Nat Med       Date:  2010-05-30       Impact factor: 53.440

6.  Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor.

Authors:  Y Kawakami; S Eliyahu; C H Delgado; P F Robbins; L Rivoltini; S L Topalian; T Miki; S A Rosenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

Review 7.  Plasticity of CD4(+) FoxP3(+) T cells.

Authors:  Xuyu Zhou; Samantha Bailey-Bucktrout; Lukas T Jeker; Jeffrey A Bluestone
Journal:  Curr Opin Immunol       Date:  2009-06-06       Impact factor: 7.486

Review 8.  Prevention of human papillomavirus infections and associated diseases by vaccination: a new hope for global public health.

Authors:  Diane M Harper
Journal:  Public Health Genomics       Date:  2009-08-11       Impact factor: 2.000

9.  XMRV is present in malignant prostatic epithelium and is associated with prostate cancer, especially high-grade tumors.

Authors:  Robert Schlaberg; Daniel J Choe; Kristy R Brown; Harshwardhan M Thaker; Ila R Singh
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-08       Impact factor: 11.205

10.  Prevalence and significance of HER-2/neu expression in early epithelial ovarian cancer.

Authors:  S C Rubin; C L Finstad; M G Federici; L Scheiner; K O Lloyd; W J Hoskins
Journal:  Cancer       Date:  1994-03-01       Impact factor: 6.860

View more
  5 in total

Review 1.  Nonviral oncogenic antigens and the inflammatory signals driving early cancer development as targets for cancer immunoprevention.

Authors:  Nina J Chu; Todd D Armstrong; Elizabeth M Jaffee
Journal:  Clin Cancer Res       Date:  2015-01-26       Impact factor: 12.531

2.  Potential use of vaccines in the primary prevention of breast cancer in high-risk patients.

Authors:  Matteo Lazzeroni; Davide Serrano
Journal:  Breast Care (Basel)       Date:  2012-08       Impact factor: 2.860

3.  Experimental autoimmune breast failure: a model for lactation insufficiency, postnatal nutritional deprivation, and prophylactic breast cancer vaccination.

Authors:  Pavani Kesaraju; Ritika Jaini; Justin M Johnson; Cengiz Z Altuntas; Jessica J Gruden; Cagri Sakalar; Vincent K Tuohy
Journal:  Am J Pathol       Date:  2012-09       Impact factor: 4.307

4.  Placenta-derived gp96 as a multivalent prophylactic cancer vaccine.

Authors:  Bao Zhao; Yanzhong Wang; Bo Wu; Shan Liu; Erjie Wu; HongXia Fan; MingMing Gui; Lizhao Chen; Changfei Li; Ying Ju; Wei Zhang; Songdong Meng
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

Review 5.  Allergens are not pathogens: why immunization against allergy differs from vaccination against infectious diseases.

Authors:  Richard Weiss; Sandra Scheiblhofer; Josef Thalhamer
Journal:  Hum Vaccin Immunother       Date:  2013-11-26       Impact factor: 3.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.